Rhythm Pharmaceuticals Inc (RYTM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.97B
Last updated: Nov 17, 2026 at 11:06 AM ET
Rhythm Pharmaceuticals Inc (RYTM) Earnings: Report Dates and Results
Rhythm Pharmaceuticals (RYTM) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Rhythm Pharmaceuticals reported EPS of -$0.61, above the -$0.68 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
RYTM has an expected report date of Feb 24, 2027.
RYTM Earnings Call
The latest RYTM earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 37 quarters below that had an estimate, RYTM beat 21, missed 13 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $92.13M, up 79.6% from $51.30M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.61 | -$0.68 | -$0.85 - -$0.66 | +10.29% | Beat | N/A | 13 | N/A | Nov 3, 2026 | $92.13M |
| Jun 30, 2026 | -$0.73 | -$0.81 | -$1.02 - -$0.67 | +9.88% | Beat | N/A | 11 | 2 up, 0 down | Aug 4, 2026 | $71.25M |
| Mar 31, 2026 | -$0.83 | -$0.86 | -$0.98 - -$0.65 | +3.49% | Beat | N/A | 10 | 2 up, 2 down | May 5, 2026 | $60.11M |
| Dec 31, 2025 | -$0.73 | -$0.79 | -$0.95 - -$0.27 | +7.59% | Beat | N/A | 12 | 1 up, 1 down | Feb 26, 2026 | $57.25M |
| Sep 30, 2025 | -$0.82 | -$0.73 | -$0.86 - -$0.51 | -12.33% | Miss | N/A | 10 | 1 up, 2 down | Nov 4, 2025 | $51.30M |
| Jun 30, 2025 | -$0.75 | -$0.67 | -$0.88 - -$0.49 | -11.94% | Miss | N/A | 10 | 1 up, 2 down | Aug 5, 2025 | $48.50M |
| Mar 31, 2025 | -$0.81 | -$0.68 | -$0.80 - -$0.51 | -19.12% | Miss | N/A | 7 | 0 up, 2 down | May 7, 2025 | $32.70M |
| Dec 31, 2024 | -$0.72 | -$0.73 | -$1.03 - -$0.52 | +1.37% | Beat | N/A | 7 | 1 up, 0 down | Feb 26, 2025 | $41.83M |
| Sep 30, 2024 | -$0.73 | -$0.87 | -$1.23 - -$0.57 | +16.09% | Beat | N/A | 11 | 0 up, 0 down | Nov 5, 2024 | $33.25M |
| Jun 30, 2024 | -$0.55 | -$0.72 | -$0.80 - -$0.60 | +23.61% | Beat | N/A | 9 | 0 up, 0 down | Aug 6, 2024 | $29.08M |
| Mar 31, 2024 | -$2.35 | -$2.39 | -$2.41 - -$0.61 | +1.67% | Beat | N/A | 9 | 0 up, 0 down | May 7, 2024 | $25.97M |
| Dec 31, 2023 | -$0.70 | -$0.70 | -$0.79 - -$0.62 | 0.00% | In line | N/A | 9 | 0 up, 0 down | Feb 22, 2024 | $24.23M |
| Sep 30, 2023 | -$0.76 | -$0.76 | -$0.97 - -$0.63 | 0.00% | In line | N/A | 9 | 1 up, 2 down | Nov 7, 2023 | $22.50M |
| Jun 30, 2023 | -$0.82 | -$0.78 | -$0.95 - -$0.66 | -5.13% | Miss | N/A | 8 | 2 up, 0 down | Aug 1, 2023 | $19.22M |
| Mar 31, 2023 | -$0.92 | -$0.77 | -$0.80 - -$0.58 | -19.48% | Miss | N/A | 7 | 0 up, 2 down | May 2, 2023 | $11.47M |
| Dec 31, 2022 | -$0.75 | -$0.81 | -$1.03 - -$0.70 | +7.41% | Beat | N/A | 9 | 0 up, 0 down | Mar 1, 2023 | $8.79M |
| Sep 30, 2022 | -$0.79 | -$0.98 | -$1.08 - -$0.86 | +19.39% | Beat | N/A | 8 | 2 up, 2 down | Nov 8, 2022 | $4.28M |
| Jun 30, 2022 | -$0.89 | -$1.03 | -$1.09 - -$0.37 | +13.59% | Beat | N/A | 9 | 2 up, 0 down | Aug 2, 2022 | $9.07M |
| Mar 31, 2022 | -$1.05 | -$1.04 | -$1.08 - -$0.82 | -0.96% | Miss | N/A | 9 | 1 up, 1 down | May 3, 2022 | $1.50M |
| Dec 31, 2021 | -$0.85 | -$0.91 | -$1.14 - -$0.75 | +6.59% | Beat | N/A | 7 | N/A | Mar 1, 2022 | $1.82M |
| Sep 30, 2021 | -$0.70 | -$0.83 | -$0.89 - -$0.73 | +15.66% | Beat | N/A | 6 | N/A | Nov 2, 2021 | $1.03M |
| Jun 30, 2021 | -$0.70 | -$0.74 | -$0.76 - -$0.56 | +5.41% | Beat | N/A | 7 | N/A | Aug 3, 2021 | $274000 |
| Mar 31, 2021 | -$1.16 | $0.30 | -$0.78 - $1.36 | -486.67% | Miss | N/A | 8 | N/A | May 3, 2021 | $35000 |
| Dec 31, 2020 | -$0.79 | -$0.79 | -$0.85 - -$0.76 | 0.00% | In line | N/A | 8 | N/A | Mar 1, 2021 | N/A |
| Sep 30, 2020 | -$0.77 | -$0.80 | -$0.86 - -$0.74 | +3.75% | Beat | N/A | 8 | N/A | Nov 2, 2020 | N/A |
| Jun 30, 2020 | -$0.71 | -$0.82 | -$0.89 - -$0.78 | +13.41% | Beat | N/A | 8 | N/A | Aug 3, 2020 | N/A |
| Mar 31, 2020 | -$0.78 | -$0.82 | -$0.99 - -$0.74 | +4.88% | Beat | N/A | 8 | N/A | May 4, 2020 | N/A |
| Dec 31, 2019 | -$0.78 | -$0.89 | -$1.06 - -$0.72 | +12.36% | Beat | N/A | 8 | N/A | Mar 2, 2020 | N/A |
| Sep 30, 2019 | -$1.04 | -$1.10 | -$1.25 - -$0.75 | +5.45% | Beat | N/A | 7 | N/A | Nov 1, 2019 | N/A |
| Jun 30, 2019 | -$1.24 | -$0.85 | -$0.96 - -$0.72 | -45.88% | Miss | N/A | 7 | N/A | Jul 29, 2019 | N/A |
| Mar 31, 2019 | -$0.84 | -$0.73 | -$0.84 - -$0.54 | -15.07% | Miss | N/A | 5 | N/A | May 3, 2019 | N/A |
| Dec 31, 2018 | -$0.74 | -$0.57 | -$0.66 - -$0.46 | -29.82% | Miss | N/A | 5 | N/A | Mar 8, 2019 | N/A |
| Sep 30, 2018 | -$0.52 | -$0.61 | N/A | +14.75% | Beat | N/A | N/A | N/A | Nov 9, 2018 | N/A |
| Jun 30, 2018 | -$0.52 | -$0.47 | -$0.56 - -$0.40 | -10.64% | Miss | N/A | 3 | N/A | Aug 8, 2018 | N/A |
| Mar 31, 2018 | -$0.60 | -$0.42 | N/A | -42.86% | Miss | N/A | 2 | N/A | May 14, 2018 | N/A |
| Dec 31, 2017 | -$0.41 | -$0.46 | -$0.55 - -$0.38 | +10.87% | Beat | N/A | 3 | N/A | Mar 12, 2018 | N/A |
| Sep 30, 2017 | -$0.66 | -$0.56 | N/A | -17.86% | Miss | N/A | N/A | N/A | Oct 5, 2017 | N/A |
| Jun 30, 2017 | -$0.41 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 30, 2017 | N/A |
| Mar 31, 2017 | -$0.29 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 24, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.11, after -$4.35 the year before. It was -$1.77 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.11 | N/A |
| Dec 31, 2024 | -$4.35 | N/A |
| Dec 31, 2023 | -$3.20 | N/A |
| Dec 31, 2022 | -$3.48 | N/A |
| Dec 31, 2021 | -$3.41 | N/A |
| Dec 31, 2020 | -$3.05 | N/A |
| Dec 31, 2019 | -$3.90 | N/A |
| Dec 31, 2018 | -$2.38 | N/A |
| Dec 31, 2017 | -$1.77 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,600 words across 20 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,576 | 20 | |
| 2026Q2 | Jun 30, 2026 | 7,687 | 21 | |
| 2026Q1 | Mar 31, 2026 | 6,814 | 16 | |
| 2025Q4 | Dec 31, 2025 | 8,678 | 17 | |
| 2025Q3 | Sep 30, 2025 | 6,898 | 17 | |
| 2025Q2 | Jun 30, 2025 | 4,889 | 12 | |
| 2025Q1 | Mar 31, 2025 | 5,292 | 12 | |
| 2024Q4 | Dec 31, 2024 | 7,457 | 16 |
2026Q3 Earnings Call
Opening remarks
Dave Connolly Head of Investor Relations Thank you, Michelle. I am Dave Connolly here at Rhythm Pharmaceuticals. For those of you participating on the conference call, our slides can be accessed and controlled by going to the investor section of our website, ir.rhythmtx.com. Last night, we issued a press release announcing the amendment to our bivamelagon licensing agreement, and this morning, we issued our press release that provides our Q3 2026 financial results and a business update. Both press releases are available on our website. Our agenda is listed on slide 2. On the call today are David Meeker, our Chairman, Chief Executive Officer, and President, Jennifer Lee, Executive Vice President, Head of North America, Hunter Smith, Chief Financial Officer, and Yann Mazabraud, Executive Vice President, Head of International, who is on the line joining us from Europe. On slide 3, I will remind you this call contains remarks concerning future expectations, plans, and prospects, which constitute forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent annual or quarterly reports on file with the SEC. In addition, any forward-looking statements represent our views as of today and should not be relied upon as representing our views as of any subsequent dates. We specifically disclaim any obligation to update such statements. With that, I will turn the call over to David Meeker, who will begin on slide 5.
David Meeker Chairman, CEO, and President Thank you, Dave. Good morning, and thank you for joining today. Rhythm continues to execute on multiple fronts, and we are excited to update you on our progress. Let us start on slide 5. We are very pleased to announce a strong third quarter, driven by an excellent start to the U.S. launch. Start forms are growing as expected, with encouraging market access translating to strong revenue performance of $92 million for the quarter. Jennifer will provide more details. We are excited about launching in Japan, with the first commercial patients already on treatment. We have every expectation that Japan will become our second-largest market. Yann will provide more color there. I will say more about our clinical development plans and the recently announced amendment to our LG Chem deal over the next couple slides. Slide 6 is a reminder of our three major strategic pillars. The first pillar is the genetic indications, where we have multiple approvals, and we will be looking to expand the list of genes we are investigating. More to come on that in 2027. Second is HO, where we have a growing conviction in the magnitude of this opportunity globally, as you will hear more about today.
Frequently Asked Questions About RYTM
When is Rhythm Pharmaceuticals's next earnings date?
Rhythm Pharmaceuticals's next earnings report is expected for Feb 24, 2027.
Did RYTM beat earnings estimates last quarter?
Yes. Rhythm Pharmaceuticals reported EPS of -$0.61 for the quarter ended Sep 30, 2026, above the -$0.68 estimate, a 10.29% surprise.
What EPS do analysts expect from RYTM next quarter?
The consensus EPS estimate for Rhythm Pharmaceuticals for the quarter ending Dec 31, 2026 is -$1.59 from 21 analysts, with estimates from -$5.46 to -$0.07.
How often does RYTM beat earnings estimates?
Rhythm Pharmaceuticals beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of -1.35%.
RYTM pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors